Metabolic effects of oestrogen compounds in men with low testosterone

Phase 4

Recruiting

• Conditions: Metabolic effects in men with low testosterone; Metabolic and Endocrine - Normal metabolism and endocrine development and function

• Registration Number: ACTRN12608000537358
• Lead Sponsor: Department of Endocrinology, St Vincent's Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2008-10-24
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 24

Inclusion Criteria

Hypogonadism (prostate cancer patients on androgen deprivation therapy for at least 6 months)

Exclusion Criteria

Androgen deprivation for less than 6 months, metastasis, cancer in other tissues than prostate, diabetes, kidney and liver disease, deep vein thrombosis

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Growth hormone (GH) secretion after arginine stimulation, measured by GH Elisa kit, Bioclone Australia[At baseline and after 1 and 6 months of treatment]

Secondary Outcome Measures

Name	Time	Method
Whole body protein turnover by leucine turnover technique.[At baseline and after 1 and 6 months of treatment];Fat and lean body mass by Dual energy xray absorptiometry (DEXA).[At baseline and after 1 and 6 months of treatment];Measurements of fat oxidation by indirect calorimetry[At baseline and after 1 and 6 months of treatment];Biochemical markers of growth hormone - insulin-like growth factor I (GH-IGFI) axis measured by radioimmuno assay.[At baseline and after 1 and 6 months of treatment]